Skip to content

Celecoxib in Postoperative Analgesia for Radius Fracture Surgery

Celecoxib for Treatment of Postoperative Pain After Osteosynthesis of Distal Radius Fracture

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05288374
Enrollment
42
Registered
2022-03-21
Start date
2022-02-10
Completion date
2023-12-31
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

Postoperative pain, Distal radius fracture, Osteosynthesis, Celecoxib

Brief summary

Patients scheduled for elective osteosynthesis of the distal radius will be randomized to receive celecoxib 100 mg orally (PO) at 6 in the morning before surgery and every 12 hours for 2 days thereafter, or a placebo pill in the same regimen. After surgery under general anaesthesia, they will receive paracetamol 1 g intravenously (IV) every 6 hours and if pain intensity is greater than 4 on a numeric rating scale (NRS) of 0-10, piritramid 15 mg intramuscularly (IM) will be administered. Pain intensity, piritramid consumption and side effects of treatment will be recorded in a questionnaire for 2 days.

Detailed description

A prospective single-blinded randomized study will be performed in patients of the Orthopaedic Clinic of the 3rd Medical Faculty of Charles University (3LF UK) and the Faculty Hospital Kralovske Vinohrady (FHKV) scheduled for elective osteosynthesis of the distal radius. The expected number of participants is 25 in each arm of the study. They will be randomized by envelope method into an non-steroidal analgesic (NSA) group, which will receive celecoxib at 6 in the morning before surgery, and a C group, which will receive a placebo pill prepared by the hospital pharmacy. General anesthesia will be performed in both groups in the standard way using propofol, sufentanil and sevoflurane 1 minimal alveolar concentration (MAC) with air and oxygen at 40% concentration. At the end of surgery, each patient will be given paracetamol 1 g intravenously (IV) and ondansetron 4 mg IV. Pain intensity after surgery will be measured on a numerical rating scale (NRS) 0-10. For postoperative analgesia, both groups will receive paracetamol 1 g IV. every 6 hours, and for NRS\>4 pain intensity, piritramid 15 mg intramuscularly (IM). The NSA group will receive celecoxib 100 mg orally (PO) at 6 in the morning and 6 in the afternoon, and group C will receive placebo at the same interval. Parameters to be monitored will be postoperative pain intensity for the primary objective, and opioid piritramid consumption and side effects of the treatment for the secondary objectives. NRS, number of doses of piritramid and side effects will be recorded in a coded questionnaire.

Interventions

Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery

DRUGPlacebo

Administering placebo regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery

Sponsors

Faculty Hospital Kralovske Vinohrady
CollaboratorOTHER_GOV
Charles University, Czech Republic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Placebo pill provided by a hospital pharmacy will be administered orally on the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.

Intervention model description

Celecoxib 100 mg orally on the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for osteosynthesis of distal radius fracture

Exclusion criteria

* Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib * History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. * Patients who have demonstrated allergic-type reactions to sulfonamides. * Inability to understand the questionnaire

Design outcomes

Primary

MeasureTime frameDescription
Postoperative pain intensityup to 2 daysIntensity of pain measured by numeric rating scale (NRS) 0-10

Secondary

MeasureTime frameDescription
Number of piritramid injection3 daysPiritramid 15 mg intramuscularly will be administered if numeric rating scale (NRS 0-10) of pain is NRS\>4
Side effects of treatment3 daysIncidence of stomach pain, heartburn, gas, diarrhea, constipation, nausea, vomiting, dizziness, others

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026